Invokana (Canagliflozin) Lawsuits

A large number of Invokana (Canagliflozin) lawsuits are filed during the past several decades.  As of August 2017, there are 642 activities pending against Johnson & Johnson, Invokana’s manufacturer.

The drug has proven successful in treating Type 2 diabetes, but is connected with numerous, serious unwanted effects, such as diabetic ketoacidosis, kidney damage, heart attack, and stroke.  Other drugs, called SGLT2 inhibitors also have become the topic of the warnings and lawsuits.

The FDA has released numerous warnings about the use of Invokana and other SGLT2 inhibitors:

  • Warning for Leg and Foot Amputation: In May 2017 the FDA required that Invokana include its “most prominent” warning, a black box warning, on product packaging. The FDA stated, “Based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.” The upgraded warning in May 2017 was based on the results of two clinical trials which showed that patients with type 2 diabetes were twice more likely to need an amputation if they took Invokana than if they took a placebo.
  • Warnings for Ketoacidosis: From March 2013, when Invokana was approved, to October 2015, FDA received reports of 73 cases of ketoacidosis. Ketoacidosis is caused by the accumulation of chemicals called ketones in the kidneys. The FDA issued a warning in December 2015.
  • Acute Kidney Injury: In June 2016, the FDA strengthened the acute kidney injury (AKI) warning for Invokana. The FDA received reports of more than 100 confirmed cases, some requiring hospitalization and dialysis.
  • Blood and Urinary Tract Infections: In December 2015 the FDA issued a warning about a class of drugs, which included Invokana, citing a risk of serious blood and urinary tract infections. The agency cited 19 confirmed cases.
  • Cardiovascular Issues and Acute Pancreatitis: Some recent studies have shown a link between Invokana, other SGLT2 inhibators and cardiovascular ailments, including stroke, blood clots (thromboembolic events) and heart attacks. In 2016 the FDA said that it had received reports of users of Invokana and other SGLT2 inhibitors suffering from cases of acute pancreatitis.

Multidistrict Litigation in Invokana (Canagliflozin) Lawsuits

Abilify cases were united with the intention of MDL in October 2016 to simplify and combine the lawsuit procedure.  Examples from around the state could be united in One courtroom and

Judge in multidistrict litigation so as to unite and simplify regeneration.  If the cases aren’t settled or ignored, the presiding judge and parties involved might select one or more agents case to litigate.  All these “bellwether” instances provide advice to additional plaintiffs about if and how to continue.  The plaintiffs allege that “Invokana can cause an Assortment of injuries, such as diabetic ketoacidosis and kidney impairment, which suspect Janssen Pharmaceuticals, Inc. (Janssen), that developed and manufactured the drug, failed to adequately test the medication and warn of its dangers.”

Invokana (Canagliflozin) Uses

Invokana assists patients with type 2 diabetes control blood glucose levels.  It works by helping the kidneys in eliminating blood in the body.  It does so by blocking SGLT2 carriers which generally help reabsorb and discharge glucose back into the blood flow.  When patients utilize Invokana, they excrete excessive sugars during urination, instead of the sugars creating up in their blood.

How Invokana (Canagliflozin)Works

Invokana along with other SGLT2 works by making sure that excess sugar in the blood isn’t reabsorbed by the kidneys and is rather removed from